Expanding circle of inhibition:: Small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents

被引:70
|
作者
Zeitlin, Benjamin D.
Zeitlin, Isaac J.
Nor, Jacques E. [1 ]
机构
[1] Univ Michigan, Angiogenesis Res Lab, Sch Dent, Dept Restorat Sci, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1200/JCO.2007.15.7693
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The specific targeting of diseases, particularly cancer, is a primary aim in drug development, as specificity reduces unwelcome effects on healthy tissue and increases drug efficacy at the target site. Drug specificity can be increased by improving the delivery system or by selecting drugs with affinity for a molecular ligand specific to the disease state. The role of the prosurvival Bcl-2 protein in maintaining the normal balance between apoptosis and cellular survival has been recognized for more than a decade. Bcl-2 is vital during development, much less so in adults. It has also been noted that some cancers evade apoptosis and obtain a survival advantage through aberrant expression of Bcl-2. The new and remarkably diverse class of drugs, small-molecule inhibitors of Bcl-2 (molecular weight approximately 400 to 800 Daltons), is examined herein. We present the activities of these compounds along with clinical observations, where available. The effects of Bcl-2 inhibition on attenuation of tumor cell growth are discussed, as are studies revealing the potential for Bcl-2 inhibitors as antiangiogenic agents. Despite an enormous body of work published for the Bcl- 2 family of proteins, we are still learning exactly how this group of molecules interacts and indeed what they do. The small- molecule inhibitors of Bcl-2, in addition to their therapeutic potential, are proving to be an important investigative tool for understanding the function of Bcl-2.
引用
收藏
页码:4180 / 4188
页数:9
相关论文
共 50 条
  • [21] An orally delivered small-molecule formulation with antiangiogenic and anticancer activity
    Ofra Benny
    Ofer Fainaru
    Avner Adini
    Flavia Cassiola
    Lauren Bazinet
    Irit Adini
    Elke Pravda
    Yaakov Nahmias
    Samir Koirala
    Gabriel Corfas
    Robert J D'Amato
    Judah Folkman
    Nature Biotechnology, 2008, 26 : 799 - 807
  • [22] An orally delivered small-molecule formulation with antiangiogenic and anticancer activity
    Benny, Ofra
    Fainaru, Ofer
    Adini, Avner
    Cassiola, Flavia
    Bazinet, Lauren
    Adini, Irit
    Pravda, Elke
    Nahmias, Yaakov
    Koirala, Samir
    Corfas, Gabriel
    D'Amato, Robert J.
    Folkman, Judah
    NATURE BIOTECHNOLOGY, 2008, 26 (07) : 799 - 807
  • [23] Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
    Shetu, Shaila A.
    Bandyopadhyay, Debasish
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
  • [24] Understanding and overcoming resistance of MDM2 and Bcl-2/Bcl-xL small-molecule inhibitors in human cancer
    Wang, Shaomeng
    Hoffman-Luca, Cassandra Gianna
    Bai, Longchuan
    Lu, Jianfeng
    McEachem, Donna
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [25] Design, synthesis and biological evaluation of novel small-molecule inhibitors of Bcl-2 and Bcl-xL proteins.
    Ding, K
    Nikolovska-Coleska, Z
    Wang, RX
    Zhang, MC
    Liu, ML
    Yang, DJ
    Tomita, Y
    Wang, SM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U196 - U196
  • [26] Computer-assisted identification of small-molecule Bcl-2 modulators
    Fuellbeck, Melanie
    Gebhardt, Nina
    Hossbach, Julia
    Daniel, Peter T.
    Preissner, Robert
    COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2009, 33 (06) : 451 - 456
  • [27] Antiangiogenic agents: an update on small molecule VEGFR inhibitors
    Schenone, S.
    Bondavalli, F.
    Botta, M.
    CURRENT MEDICINAL CHEMISTRY, 2007, 14 (23) : 2495 - 2516
  • [28] Discovery and therapeutic potential of novel Bcl-2/Bcl-xL small-molecule inhibitors in human breast cancer.
    Xu, L
    Wang, G
    Tang, N
    Nikolovska-Coleska, Z
    Wang, R
    Demchik, L
    Liu, M
    Zhang, M
    Roller, P
    Tomita, Y
    Yang, D
    Rae, J
    Lippman, ME
    Wang, S
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S66 - S66
  • [29] Small-molecule inhibitors of MDM2 as new anticancer therapeutics
    Dickens, Michael P.
    Fitzgerald, Ross
    Fischer, Peter M.
    SEMINARS IN CANCER BIOLOGY, 2010, 20 (01) : 10 - 18
  • [30] DISCOVERY OF SMALL MOLECULAR Bcl-2 INHIBITORS AS POTENTIAL ANTICANCER DRUGS
    Li, S.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2002, 58 : C231 - C231